Changes in Beneficial Ownership · 4
Biogen Inc.
BIIBNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-06-09
- Issuer
- BIOGEN INC.
- Issuer CIK
- 0000875045
- Trading symbol
- BIIB
Reporting owner 1
- Name
- Pangalos Menelas N
- Reporting owner CIK
- 0002001873
- Relationship
- Director
- Address
- C/O BIOGEN INC. 225 BINNEY, CAMBRIDGE, MA, 02142
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-09 | M · Form 4 | 2,370 | A | 0 | 2,370 | D |
| Common Stock | 2026-06-09 | A · Form 4 | 1,505[F1] | A | 0 | 3,875 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Unit | 0 | 2026-06-09 | M · Form 4 | 2,370 | D | 0 | [F2] | 2026-06-17 | Common Stock | 2,370 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Wendell Taylor, attorney-in-fact for Dr. Pangalos
- Date
- 2026-06-11
Company context
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, Instagram, LinkedIn, X, YouTube.